Core Viewpoint - The company has received high-tech enterprise certification for multiple subsidiaries, which will allow them to benefit from preferential tax policies for the next three years [1][2]. Group 1: Certification Details - The company's subsidiary, Xuancheng Meinuohua Pharmaceutical Co., Ltd., received a high-tech enterprise certificate from the Anhui Provincial Department of Industry and Information Technology, with a certificate number GR202534001271, issued on October 28, 2025, valid for three years [1]. - The wholly-owned subsidiary, Ningbo High-tech Zone Meinuohua Pharmaceutical Innovation Research Institute Co., Ltd., received a high-tech enterprise certificate from the Ningbo Science and Technology Bureau, with a certificate number GR202533101572, issued on December 26, 2025, valid for three years [1]. - Another wholly-owned subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., also received a high-tech enterprise certificate from the Ningbo Science and Technology Bureau, with a certificate number GR202533102561, issued on December 26, 2025, valid for three years [1]. Group 2: Tax Benefits - Following the certification, Xuancheng Meinuohua, the Innovation Research Institute, and Meinuohua Tiankang will enjoy national preferential policies for high-tech enterprises, allowing them to pay a corporate income tax rate of 15% for the years 2025, 2026, and 2027 [2].

Core Viewpoint - The company Minohua announced that its subsidiaries Xuancheng Minohua, Innovation Research Institute, and Minohua Tiankang have received the "High-tech Enterprise Certificate," which is valid for three years [1] Group 1 - Xuancheng Minohua's certificate is effective until October 28, 2025, while the Innovation Research Institute and Minohua Tiankang's certificates are effective until December 26, 2025 [1] - The recognition is a re-certification following the expiration of the previous certificates [1] - The three subsidiaries will be able to pay corporate income tax at a rate of 15% from 2025 to 2027 [1]

| | | 宁波美诺华药业股份有限公司 序 号 受托方 产品名称 产品 类型 产品 期限 金额 （万元） 已履行的 审议程序 1 招商银行 招商银行单位大额存单 2025 年第 5855 期 大额 存单 - 1,000 已经公司 2025 年 4 月 17 日召开的第五届董 事会第十三次会议，以 及 2025 年 5 月 8 日召 开的 2024 年年度股东 大会审议通过 合计 - - - 1,000 - 本次使用闲置募集资金进行现金管理具体情况如下： 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 特别风险提示：公司购买的上述理财产品为固定利率收益型的投资产品， 属于低风险投资产品，但不排除该项投资可能受到市场波动、宏观金融政策变化 等影响。 一、本次现金管理概况 （一）本次现金管理目的 为进一步提高募集资金使用效率，宁波美诺华药业股份有限公司（以下简称 "公司"）于 2026 年 1 月 20 日使用闲置募集资金进行现金管理。本次使用闲置 募集资金进行现金管理不会 ...

Group 1 - The core viewpoint of the news is that Meinuohua's stock performance and financial metrics indicate a mixed outlook, with a slight decline in stock price and significant changes in financing activities [1][2] Group 2 - On January 16, Meinuohua's stock price fell by 0.72%, with a trading volume of 102 million yuan. The financing buy amount was 11.19 million yuan, while the financing repayment was 15.28 million yuan, resulting in a net financing buy of -4.09 million yuan [1] - As of January 16, the total financing and securities balance for Meinuohua was 22.8 million yuan, accounting for 5.11% of the circulating market value, which is above the 50% percentile level over the past year [1] - The company had no short selling activity on January 16, with a short selling balance of 2069 yuan, indicating a low level compared to the 30% percentile over the past year [1] Group 3 - As of September 30, the number of shareholders for Meinuohua increased to 34,700, a rise of 7.22%, while the average circulating shares per person decreased by 5.48% to 6,229 shares [2] - For the period from January to September 2025, Meinuohua reported a revenue of 1.117 billion yuan, representing a year-on-year growth of 17.67%, and a net profit attributable to shareholders of 95.93 million yuan, up by 51.66% [2] Group 4 - Meinuohua has distributed a total of 149 million yuan in dividends since its A-share listing, with 50.58 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included Xinhua Preferred Dividend Mixed A (519087) as the seventh largest shareholder, holding 1.3129 million shares as a new shareholder [3]

Group 1 - The company will hold its first extraordinary general meeting of 2026 on February 2, 2026, at 14:00 [2][4] - Shareholders can vote through the Shanghai Stock Exchange's online voting system during specified time slots on the meeting day [2][4] - The meeting will include both on-site and online voting methods, with the location being in Ningbo, Zhejiang Province [4][10] Group 2 - The board of directors has proposed to adjust the conversion price of the "Meinuo Convertible Bonds" downwards due to the stock price being below 90% of the current conversion price for at least 15 trading days within a 30-day period [33][41] - The proposed adjustment will be submitted for shareholder approval, requiring a two-thirds majority of the voting rights present at the meeting [33][41] - The current conversion price is set at 25.68 yuan per share, and the adjusted price must not be lower than the higher of the average trading price over the last 20 trading days prior to the meeting and the previous trading day's average [41][39] Group 3 - The company has approved daily related transactions for 2026, with an estimated amount not exceeding 60 million yuan, which has been reviewed and approved by independent directors [20][48] - The related party involved is Ningbo Kelkang Meinuo Pharmaceutical Co., Ltd., in which the company holds a 40% stake [24][25] - The transactions are deemed necessary for the company's normal operations and will not adversely affect the company's financial status or independence [20][29]

Core Viewpoint - Meinuo's stock has triggered a downward adjustment of its convertible bond conversion price due to its closing price being below the conversion price for at least 15 out of the last 30 trading days [2] Group 1 - Meinuo announced that its stock price has been below the current conversion price of 25.68 yuan per share by 90%, specifically below 23.11 yuan per share [2] - The company convened the 23rd meeting of its fifth board of directors to review and approve the proposal for the downward adjustment of the "Meinuo Convertible Bond" conversion price [2] - The board of directors has proposed to adjust the conversion price of the "Meinuo Convertible Bond" downward [2]

Group 1 - The company Meinuohua (603538) announced that it will hold its first extraordinary general meeting of shareholders in 2026 on February 2 [1]

Group 1 - The company, Meinuo, announced the approval of several key proposals during its 23rd meeting of the fifth board of directors, including the expected daily related transactions for 2026 [2] - The company proposed a downward adjustment of the conversion price for "Meinu Convertible Bonds" [2] - A proposal was made to convene the first temporary shareholders' meeting of 2026 [2]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-008 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票 系统 一、召开会议的基本情况 （一）股东会类型和届次 重要内容提示： 股东会召开日期：2026年2月2日 2026年第一次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 召开的日期时间：2026 年 2 月 2 日 14 点 00 分 召开地点：浙江省宁波市高新区梅墟街道菁华路 777 号 1 号楼 （五） ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-007 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 关于董事会提议向下修正"美诺转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至 2026 年 1 月 16 日，宁波美诺华药业股份有限公司（以下简称"公 司"）股票已出现在任意连续三十个交易日中至少有十五个交易日的收盘价格低 于当期转股价格（25.68 元/股）90%，即低于 23.11 元/股（保留两位小数）的 情形，触发"美诺转债"转股价格向下修正条款。 2026 年 1 月 16 日，公司召开第五届董事会第二十三次会议审议通过《关 于向下修正"美诺转债"转股价格的议案》，公司董事会提议向下修正"美诺转 债"转股价格。 本次向下修正"美诺转债"转股价格事项尚需提交公司股东会审议。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司 ...